Scientific program

Day 1_November 26 (Fri), 2021

Venue Songdo Convensia Grand-Ballroom
Date Nov 26 (Fri) 2021
Moderator  Shim, Myung-Sun (Hallym University, Korea)
Time table Topics Chair / Speaker 
16:00-16:10 Welcome address Kwak, Cheol (President, KUOS, Seoul National University, Korea)
16:10-16:30 Keynote Lecture Kwak, Cheol (President, KUOS, Seoul National University, Korea)
  Biochemical relapse after radical prostatectomy and efficacy of salvage radiotherapy in patients with prostate cancer Ahn, Hanjong(University of Ulsan, Korea)
16:30-17:30 Surgery (1) Byun, Seok-Soo(Seoul National University, Korea)
Uemura, Hirotsugu (Kindai University, Japan)
Takenaka, Atsushi (Tottori University, Japan)
16:30-16:45 Robot partial nephrectomy for totally endophytic tumor Seo, Seong Il (Sungkyunkwan University, Korea)
16:45-17:00 ePLND in very high risk prostate cancer Byun, Seok-Soo (Seoul National University, Korea)
17:00-17:15 Development and future vision of the Made-in Japan surgical robot system Hinata, Nobuyuki (Hiroshima University, Japan)
17:15-17:30 Q & A  
17:30-18:30 Prostate Cancer (1) Jeon, Seong Soo (President, Sungkyunkwan University, Korea)
Egawa, Shin (Jikei University, Japan)
Ou, Yen-Chuan (Tungs’ Taichung MetroHarbor Hospital, Taiwan)
17:30-17:45 Expression of PD-L1 in needle biopsy prostate cancer tissue Shim, Kang Hee (Ajou University, Korea)
17:45-18:00 Evolving landscape of prostate cancer in 2021 Kevin Lu (Taichung Veterans General Hospital, Taiwan)
18:00-18:15 Penile rehabilitation after radical prostatectomy Lee, Sung Won (Sungkyunkwan University, Korea)
18:15-18:30 Q & A  
18:30 Adjourn  


Day 2_November 27 (Sat), 2021

Venue Songdo Convensia Grand-Ballroom
Date Nov 27 (Sat) 2021
Moderator  Shim, Myung-Sun (Hallym University, Korea)
Time table Topics Chair / Speaker 
09:00-09:20  Introductory RemarksJeon, Seong Soo (President, Sungkyunkwan University, Korea)
Nonomura, Norio (Osaka University, Japan)
Chiang, Po-Hui (Chang Gung Memorial Hospital, Taiwan)
Congratulatory remarksAhn, Hanjong (University of Ulsan, Korea)
09:20-10:20 Prostate cancer (2)Kim, Sunil (Ajou University, Korea)
Nonomura, Norio (Osaka University, Japan)
Shiroki, Ryoichi (Fujita Health University, Japan)
09:20-09:35 PARP inhibitor in mCRPCKitamura, Hiroshi (Toyama University, Japan)
09:35-09:50 Germline genetic variants in prostate cancer patients in JapanTerada, Naoki (Miyazaki University, Japan)
09:50-10:05 Current status and challenges of PSA screening in Korea Ko, Young Hwii  (Yeungnam University, Korea)
10:05-10:20 Q & A 
10:20-10:40 Coffee Break 
10:40-11:55 Kidney cancerSong, Cheryn (University of Ulsan, Korea)
Kimura, Takahiro (Jikei University, Japan)
Pang, ST Jacob (Chang Gung Memorial Hospital, Taiwan)
10:40-10:55 1st line IO treatment for mRCC: Real word dataKondo, Tsunenori (Tokyo Women's Medical University, Japan)
10:55-11:10 Current status and future prospect of IO-TKI combined therapy for metastatic renal cell carcinomaMiyake, Hideaki (Hamamatsu University, Japan)
11:10-11:25 Real world therapeutic pattern for recurrent localized kidney cancer in KoreaKim, Sung Han (National Cancer Center, Korea)
11:25-11:40 Pathological node-positive renal cell carcinoma is associated with worse survival outcome: A recall for TMN staging revision.Yu, Kai-Jie(Chang Gung Memorial Hospital, Taiwan)
11:40-11:55 Q & A 
11:55-13:30 Lunch 
13:30-14:45 Urothelial cancerSeo, Ho Kyung (National Cancer Center, Korea)
Nishiyama, Hiroyuki (Tsukuba University, Japan)
Chiang, Po-Hui (Chang Gung Memorial Hospital, Taiwan)
13:30-13:45 Current evidence for systemic treatment for untreated metastatic urothelial carcinomaInokuchi, Junichi (Kyushu University, Japan)
13:45-14:00 The role of Enfortumabvedotin in advanced urothelial carcinoma Park, Inkeun (Gachon University, Korea)
14:00-14:15 Prognostic and Predictive Factors for metastatic urothelial carcinoma patients treated with PembrolizumabKawashima, Atsunari (Osaka University, Japan)
14:15-14:30 Clinical outcome of urachal cancer in Korean patients: multi-institutional studyYu, Young Dong (Cha Medical University, Korea)
14:30-14:45 Neoadjuvant immune check point inhibitors for localized bladder cancer-real world experience sharing.Luo, Hao Lun(Chang Gung Memorial Hospital, Taiwan)
14:45-15:10 Coffee Break 
15:10-16:25  Research Yun, Seok Joong (Chungbuk National University, Korea)
Chang, Chao-Hsiang (China Medical University, Taiwan)
15:10-15:25 Germline genetic variants in prostate cancer patients in Korea Ha, Hong Koo (Pusan National University, Korea)
15:25-15:40 The gut microbiome and prostate cancerFujita, Kazutoshi (Kindai University, Japan)
15:40-15:55 Development of AI to improve outcomes of TUR-BTIkeda, Atsushi (Tsukuba University, Japan)
15:55-16:10 MiR-26a-5p as a useful therapeutic target for upper tract urothelial carcinoma by regulating WNT5A/B-catenin signalingChung, Yueh Hua (Chang Gung Memorial Hospital, Taiwan)
16:10-16:25 Q & A 
16:25-17:25 Surgery (2)Jeong, Byong Chang (Sungkyunkwan University, Korea)
Eto, Masatoshi (Kyushu University, Japan)
Wu, Wen-Jeng (Kaohsiung Municipal Ta-Tung Hospital, Taiwan)
16:25-16:40 Technique for Extended PLND and tip for preventing of symptomatic lymphocele during RC in MIBCJang, Won Sik (Yonsei University, Korea)
16:40-16:55 Prostate surgery: Da Vinci SP (single port) radical prostatectomy Kang, Sung-Gu (Korea University, Korea)
16:55-17:10 12 year experiences of HIFU for the treatment of prostate cancerChiang, Po-Hui (JhongSiao Urological Hospital, Taiwan)
17:10-17:25 Q & A
17:25-17:30 Closing RemarkJeon, Seong Soo (President, Sungkyunkwan University, Korea)